Your support helps make research like Professor Jenny Gamble’s possible.

Alzheimer's disease is the most common form of dementia, making up around 60-70% of the 55 million people living with dementia worldwide. These numbers are unacceptable and so far, there are no cures and nothing that can stop its progression.

“Current treatments either target the symptoms of Alzheimer’s disease, having no effect on progression, or they target amyloid deposits in the brain, but these drugs can have serious side effects and only offer a limited effect on disease progression,” explains Professor Gamble.

“When healthy vessels perform as they should, they clear debris (including amyloid) from the brain. Our approach is to mend the damaged vessels so that they can effectively clear this debris. Our drug is the first which has such a profound effect”.

As with all new drugs, the process can take 2-3 years to get through high-cost pre-clinical testing to ensure optimal drug delivery before leading to Phase 1 clinical trials. We now need your help to get us into pre-clinical testing as soon as possible to move towards this new approach to treatment.

Will you make a gift today to help advance the search for a cure for Alzheimer’s?

Background header image: This image shows the region of hippocampus in the mouse brain, which is riddled with round and fluffy-looking amyloid plaques (white). These plaques can damage the blood vessels (red), which provide a selective barrier to filter out harmful substances in and out of the brain. The hippocampus is an important storage hub for our memories, thus amyloid damage to both the brain cells (blue) and blood vessels can lead to loss of memory, a devastating symptom often seen in Alzheimer’s disease patients. Dr Ka Ka Ting, Gamble Laboratory, Centenary Institute.